The immune system and stroke: from current targets to future therapy

Simple item page
dc.check.date2019-07-19
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorMalone, Kyle
dc.contributor.authorAmu, Sylvie
dc.contributor.authorMoore, Anne C.
dc.contributor.authorWaeber, Christian
dc.contributor.funderIrish Research Councilen
dc.contributor.funderHealth Research Boarden
dc.contributor.funderSeventh Framework Programmeen
dc.contributor.funderScience Foundation Irelanden
dc.date.accessioned2018-07-27T11:03:32Z
dc.date.available2018-07-27T11:03:32Z
dc.date.issued2018-07-19
dc.date.updated2018-07-26T09:08:58Z
dc.description.abstractStroke is a major cause of morbidity and mortality worldwide. Despite the intensive search for new therapies, hundreds of agents targeting various pathophysiological mechanisms have failed clinical trials, and the thrombolytic agent tissue plasminogen activator is currently the only FDA-approved medication for the treatment of acute ischaemic stroke (AIS). The immune system is involved in all stages of stroke, from the pathogenesis of risk factors to neurotoxicity, to tissue remodelling and repair. There is a bi-directional interaction between the brain and the immune system, with stroke-induced immunosuppression and subsequent infection a principal source of patient mortality. Newer work also points to a role for the gut microbiota in the immune response to stroke, while clinical sequelae such as dementia might now also be explained in immune terms. However, the exact roles of innate and adaptive components have not been fully elucidated, with studies reporting both detrimental and beneficial functions. Time is a key determinant in defining whether immunity and inflammation are neuroprotective or neurotoxic. The local inflammatory milieu also has a clear influence on many proposed treatments. This review examines the individual components of the immune response to stroke, highlighting the most promising future stroke immunotherapies.en
dc.description.sponsorshipIrish Research Council (GOIPG/2017/431); Health Research Board (HRA-POR-2015-1236); Science Foundation Ireland (BIAP2015)en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationMalone, K., Amu, S., Moore, A. C. and Waeber, C. (2018) 'The immune system and stroke: from current targets to future therapy', Immunology and Cell Biology. doi:10.1111/imcb.12191en
dc.identifier.doi10.1111/imcb.12191
dc.identifier.issn0818-9641
dc.identifier.issn1440-1711
dc.identifier.journaltitleImmunology and Cell Biologyen
dc.identifier.urihttps://hdl.handle.net/10468/6507
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc.en
dc.relation.projectinfo:eu-repo/grantAgreement/EC/FP7::SP3::PEOPLE/631246/EU/Sphingosine kinase 2-mediated preconditioning in stroke/SPK AND STROKEen
dc.rights© 2018, John Wiley & Sons Inc. This is the peer reviewed version of the following article: Malone, K., Amu, S., Moore, A. C. and Waeber, C. (2018) 'The immune system and stroke: from current targets to future therapy', Immunology and Cell Biology. doi:10.1111/imcb.12191, which has been published in final form at https://doi.org/10.1111/imcb.12191. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.en
dc.subjectStrokeen
dc.subjectIschaemiaen
dc.subjectImmunityen
dc.subjectNeuroinflammationen
dc.titleThe immune system and stroke: from current targets to future therapyen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Malone_et_al-2018-Immunology_and_Cell_Biology.pdf
Size:
368.11 KB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacology and Therapeutics - Journal Articles